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Aim. To analyze the clinical characteristics and treatment outcomes in patients with endometrial carcinoma treated in a Latin
American institute with emphasis in patients receiving adjuvant radiotherapy. Methods. A total of 412 patients with endometrial
carcinoma admitted to our hospital between 1998 and 2008 were evaluated, retrospectively. The mean age was 55 years (28–87).
Two hundred seventy patients received RT following surgery. Stage distribution was as follows: 221 patients (54%) stage I, 86
patients (21%) stage II, and 103 patients (24.5%) stage III and 2 patients (0.5%) stage IVA. Results. Overall survival rate was 95%
at2years,84%at5years,and79%at10years.Bytheendoffollowup,338patients(82%)weredisease-free,and13(3%)werealive
with disease. Univariate and multivariate analyses identiﬁed age, grade, serosal and adnexial involvement as signiﬁcant predictors
for overall survival. Conclusion. The results of our study suggests that early-stage, low-grade endometrial cancer with no risk
factors should not receive external beam radiotherapy, intermediate risk patients should receive only vaginal vault brachytherapy,
and the use of chemotherapy with radiotherapy for patients high-risk and advanced-stage carcinoma the addition of radiotherapy
is associated with a better survival being an eﬀective therapeutic option.
1.Introduction
Endometrial carcinoma is one of the most common gyneco-
logic malignancies in Mexican women after uterine cervix,
ovarian and breast cancers [1]. In our country, cancer has
had an important rise in the last 50 years. According to
the last data from National Tumor Registry in year 2003, a
total of 71,901 new cancer cases in women were registered,
from these cases, 1552 belonged to uterine corpus carcinoma
[2]. During years 2000–2004 in our hospital 19,264 new
caseswerereportedwith64.6%(12,444)belongedtowomen.
Speciﬁcally uterine corpus carcinoma ranked the ﬁfth place
forgynecologictumorsbeingendometrioidadenocarcinoma
the most prevalent histology [3].
Fortunately,70%ofendometrialcancerpatientsarediag-
nosed with localized disease, resulting in a 5-year survival
of 95% in this subset of patients [4, 5]. The median age
at diagnosis is 62 years [6]. Risk factors for development
of this disease include obesity, diabetes, hypertension,
endogenous or exogenous estrogen, nulliparity, menopause,
family history, and endometrial hyperplasia. In addition,
with better surgical techniques, advances in radiotherapy
and chemotherapy, the mortality rate for endometrial cancer
continues to decline.
InMexico,mostendometrialcancersaresurgicallystaged
according to criteria established by the International Feder-
ation of Obstetrics and Gynecology (FIGO), this includes
an hysterectomy (TAH), bilateral salpingo-oophorectomy
(BSO),andpelvic/para-aorticlymphnodedissection(LND),
with pelvic washings and an omental biopsy [7, 8]. Manage-
ment and adjuvant treatment after surgery depends upon a
patient’s risk factor for recurrence, options include vaginal2 ISRN Oncology
vault brachytherapy (VBT), pelvic external-beam radiation
therapy (EBRT), and/or chemotherapy (CT). The most
signiﬁcant risk factorconsidered in any decision for adjuvant
therapy include age, grade, histologic type, deep of myome-
trial invasion, tumor extension, tumor extension beyond the
uterus, and lymphovascular space invasion. Depending of
theseriskfactors,patientsaregroupedintolow,intermediate
or high risk for recurrence. Most controversy and debate is
associatedwiththepatientsstratiﬁedtotheintermediate-risk
group.
In this study, we analyzed the clinical characteristics and
treatment outcomes in patients with endometrial cancer
who received adjuvant radiotherapy after surgery. Although
FIGO announced an update for endometrial cancer staging
in October 2009 [9], all the cases reviewed in this study were
staged according to FIGO 1988.
2.MaterialandMethods
A total of 869 women were admitted at the National Cancer
Institute in Mexico City between January 1998 and Decem-
ber 2008. Inclusion criteria included Mexican nationality,
>18 years old at diagnosis, stages I to IVA and histologies:
endometrioid, papillary cell, clear cell, and adenosquamous.
Patients were excluded if they received EBRT previously or
were diagnosed with metastatic disease, uterine sarcoma,
not operated and treated with EBRT only, and the presence
of another synchronic tumor (i.e., breast and endometrial
carcinoma) with the exception of nonmelanoma skin cancer.
Four Hundred and twelve women met the inclusion criteria
and were evaluated retrospectively with regard to patient
characteristics and treatment outcomes. All patients were
assessed at the time of diagnosis with physical examina-
tion, routine blood counts and biochemical proﬁle, chest
X Rays, and pelvic tomography was performed in some
women. All patients included in this study had negative
pelvic or para aortic nodes on imaging. After systematic
evaluation, 120 patients were treated with TAH-BSO, 20
patients with TAH-BSO-pelvic LND, and 271 patients with
TAH-BSO-pelvic/para aortic LND and omentum biopsy.
Histopathological and immunohistochemical assessments
were performed in all cases. The staging was based on FIGO
1988 surgical staging system. A total of 270 women received
adjuvant radiotherapy, EBRT alone was administered to 11
patients, 8 patients were administered total abdominal and
pelvic EBRT plus VBT, 241 patients received EBRT + VBT, 7
patients were administered only VBT, and 7 patients received
EBRT to retroperitoneum and pelvis besides VBT. External
beam radiotherapy was given with cobalt units and 6MV
and15MVlinearaccelerators.Acomputedtomographyscan
with 5mm cut was performed for all patients from the top
of L4 to the bottom of lesser trochanters of the femurs as
part of virtual simulation. Pelvic RT was administered with
4-ﬁeld box method with a daily dose of 2Gy to achieve a
total dose of 50Gy, in all cases, two-thirds of dose were
administered through anterior and posterior ﬁelds, and one-
third of the dose was administered through opposed lateral
ﬁelds. For anterior and posterior ﬁelds (AP/PA) the upper
limit was at the top of L5, lower ﬁeld limit was at the
bottom of the obturator foramina to cover vaginal cuﬀ,
lateral ﬁeld limits were 2cm beyond the bony margins
of the pelvic inlet. Lateral opposed ﬁelds limits were the
same as AP/PA ﬁelds in superior/inferior borders but in
front of the pubis symphysis in anterior border and at S2-
S3 level in posterior border. In patients whose para-aortic
nodes were positive after surgery (Stage III), additional
para aortic RT was administered at a total dose of 45Gy
with 1.8Gy fractions, and patients with total abdominal
radiotherapy were administered a total dose of 30Gy en
1.5Gy fractions trying to protect both kidneys and liver.
Most patients received low-dose rate brachytherapy with 2,
3, and 3.5cm cylinder applicator covering all vaginal length
with a prescribed mean dose of 35Gy at 0.5cm depth. Doses
for vagina, urinary bladder, and rectum were calculated in
all patients to be under 80% of the deﬁned doses. Side
eﬀects at vagina, urinary bladder, and rectum were classiﬁed
according to the acute and late toxicity criteria as deﬁned
by the Radiation Therapy Oncology Group (RTOG) [10].
Clinicalandradiologicalassessmentswereperformedevery3
months for the ﬁrst 2 years, every 6 months for the following
2 years, and annually thereafter. Radiographic surveillance
was not routinely performed except for suspicion of disease
recurrence or metastasis. Failures found on clinical or
radiographic examination were classiﬁed as vaginal, local-
regional (recurrence within the pelvis including vaginal
cuﬀ),ordistant(bone,lung,liver,orotherwise).Deathswere
recorded for analysis.
3.StatisticalMethods
The evaluated end point was overall survival (OS) using
the Kaplan-Meier method, and signiﬁcance was determined
by the log-rank test. Univariate and multivariate analyses
were performed using the Cox proportional hazards model.
Statistical analyses were performed using statistical package
for social sciences (SPSS) for windows version 17 (SPSS,
Chicago, IL, USA).
4. Results
The mean age was 55 years (range: 23–87 years). At the time
of diagnosis, 61 patients (14.8%) were premenopausal, and
351 (85.2%) were postmenopausal. Thirty-three percent of
patients were obese (mean BMI 28.97kg/m2), and 35.2%
of women had a concomitant disease (diabetes mellitus,
systemic arterial hypertension, or both). Clinical and patho-
logical characteristics of patients are described in Table 1.
Three hundred ﬁfty-nine patients (87.1%) had endomet-
rioid cancer (see Table 2).
Histological grades wereasfollows: 165 (40%) low grade,
115 (27.9%) intermediate grade, and 130 (31.6%) high
grade. Of the participants, 221 (53.6%) had myometrial
(greater than half of the myometrial thickness), 57 (13.8%)
had lymphovascular, 47 (11.4%) had serosal, and 38 (9.25%)
hadadnexialinvolvement.Twenty-sevenpatients(4.1%)had
para aortic lymph node involvement, and 39 patients (9.5%)ISRN Oncology 3
Table 1: Characteristics of Mexican patients with endometrial
carcinoma.
Characteristics Number of patients Percentage
412 100
Age
<45 79 19.2
45−54 108 26.2
55−64 139 33.7
65−74 61 14.8
≥75 25 6.1
Mean age 55.19 (23–87)
Menopausal status
Premenopausal 61 14.8
Postmenopausal 351 85.2
Body mass index (BMI)
<30 (kg/m2) 229 55.6
>30 (kg/m2) 136 33
Not registered 47 11.4
Mean BMI 28.97 (12.32–48.8)
Parity status
Nullipara 121 29.4
Multipara 291 70.6
Blood glucose
<100mg/dL 309 75.0
100 a 199mg/dL 83 20.1
>200mg/dL 20 4.9
Comorbid conditions
Yes 145 35.19
No 267 64.81
Diabetes mellitus (DM) 94/412 22.81
Systemic arterial hypertension
(SAH) 80/412 19.41
DM + SAH 34/412 8.25
Other comorbidities 5/412 1.21
NOS: not otherwise speciﬁed.
had pelvic lymph node involvement. FIGO stages were as
follows: 221 patients (53.7%) stage I, 86 patients (20.9%)
stage II, and 103 patients (24.9%) stage III, and 2 patients
(0.5%) stage IVA. In Table 2, pathology characteristics of the
412 patients with endometrial carcinoma are described.
From these women, 211 (51.2%) were classiﬁed as high-
risk recurrence group. Table 3 describes the frequency of
histological grade according each stage of disease.
After systematic evaluation, 120 patients were treated
with TAH-BSO, 20 patients with TAH-BSO-pelvic LND,
and 271 patients with TAH-BSO-Pelvic/para aortic LND
and omentum biopsy. Histopathological and immunohisto-
chemical assessments were performed in all cases. The stag-
ing was based on FIGO 1988 surgical staging system. A total
of 270 women received adjuvant radiotherapy, EBRT alone
wasadministeredto11patients,8patientswereadministered
whole abdominal and pelvic EBRT plus VBT, 241 patients
received EBRT + VBT, 7 patients were administered only
Table 2: Pathology characteristics for Mexican patients with
endometrial carcinoma.
Characteristic Patients Percentage
Stage FIGO 1988
IA 46 11.2
IB 96 23.3
IC 79 19.2
IIA 44 10.7
IIB 42 10.2
IIIA 47 11.4
IIIB 1 .2
IIIC 55 13.3
IVA 2 .5
Grade
1 165 40
2 115 27.9
3 130 31.6
NOS 2 0.5
Lymphovascular invasion
Yes 57 13.8
No 341 82.8
NOS 14 3.4
Number of nodes
None 168 40.8
1−10 181 43.9
11– 20 51 12.4
21– 30 4 1.0
31– 40 8 1.9
Mean of nodes obtained at surgery 5 (1–40)
Histology
Endometrioid 359 87.1
Papillary serous 21 5.1
Clear cell 10 2.4
Adenosquamous 21 5.1
Glassy cell 1 .2
Size
<3cm 66 16.0
3 −5.9cm 100 24.3
>6cm 77 18.7
NOS 169 41.0
Mean size (cm) 4.78 (0.3–20.5)
Isthmus invasion
Present 76 18.4
Absent 336 81.6
Uterine cervix involvement
Endocervical gland 52 12.6
Stromal 94 22.8
None 266 64.6
Serous Involvement
Present 47 11.4
Absent 365 88.6
Positive peritoneal washing
Present 16 3.9
Absent 352 85.4
NOS 44 10.7
Adnexial involvement
Present 38 9.2
Absent 374 90.8
Number of positive nodes
1 19/412 4.6
2 9/412 2.24 ISRN Oncology
Table 2: Continued.
Characteristic Patients Percentage
3 6/412 1.5
>3 9/412 2.2
Myometrial invasion
<1/2 138 33.5
>1/2 221 53.6
None 49 11.9
NOS 4 1.0
Para aortic node involvement
Present 17 4.1
Absent 395 95.9
Pelvic node involvement
Present 39 9.5
Absent 373 90.5
Risk categories
Low 99 24.0
Low-intermediate 55 13.3
High intermediate 47 11.4
High 211 51.2
NOS: not otherwise speciﬁed.
VBT and 7 patients received EBRT to retroperitoneum and
pelvis besides VBT. External beam radiotherapy was given
with cobalt units and 6MV and 15MV linear accelerators
Aftersurgery,radiotherapy startedin a meantime of84 days,
and although available literature states starting adjuvant RT
within ﬁrst 6 weeks or after complete healing occurs, it is
diﬃcult to reach these policies at our institute because of
the high demand of patients requiring radiotherapy and
poor availability of linear accelerators. Sixty-three percent
of patients had mild acute symptoms related to treatment,
they were prescribed pharmacologic management with no
interruptions because of severe adverse eﬀects. Seventeen
percent of patients experienced chronic symptoms, grade
2 radiation proctitis (RTOG) was the most common side
eﬀect. There were no women with acute grade 3-4 or late
3-4 gastrointestinal or genitourinary side eﬀects. Adjuvant
chemotherapy or hormone therapy used in patients was
found to have adverse pathological factors such as aﬀected
nodes or positive peritoneal washings (see Table 4).
Recurrences occurred in the ﬁrst 2 years at a rate of
18% (7–63months). Vaginal recurrence was reported in
15 patients, pelvic recurrence developed in 9, and distant
metastasis in 27 patients being lung and liver the most
common sites of recurrence. All patients with local or distant
recurrence received systemic chemotherapy. After an average
followupof49months,338patients(82%)weredisease-free,
and 13 (3.2%) were still alive with endometrial carcinoma.
By the time this analysis was done, 85 patients were death
(21%). Overall survival rate was 95% at 2 years, 84% at 5
years, and 79% at 10 years (Figure 1).
Univariate and multivariate analyses showed that age,
histological grade, serosal and adnexial involvement were
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Figure 1: Overall survival of 412 patients with endometrial
carcinoma.
signiﬁcantly associated with overall survival (P = 0.0003,
P = 0.0004, P = 0.005, and P = 0.005, resp.) (Table 5).
5. Discussion
Endometrial cancer is one of the most common gynecologic
malignancies in Mexican women, and the most common
in the United States. In 2010, it was estimated that 43,470
women were diagnosed with endometrial cancer (6% of new
cancer cases), and 7950 women will die of the disease. The
vast majority of women will fortunately survive their disease
and be rendered cured given that approximately 75% of the
patients are diagnosed with early-stage disease [11]. Usually
themedianageatdiagnosisis62years[4,5]andthemajority
of patients being postmenopausal, likewise, in the present
study, the mean age of the subjects was 55 years, and 85%
were postmenopausal. Hypertension, cardiac disease, and/or
diabetes mellitus were present in 35% of the patients at the
time of diagnosis.
The current treatment for endometrial carcinoma in-
volves the use of surgery, radiation therapy, hormone ther-
apy, and chemotherapy, either alone or sequentially. Deﬁni-
tive diagnosis requires histopathological examination, and
staging is based on FIGO surgical staging system [12].
Surgery is the mainstay treatment for most patients with
endometrial cancer. In a small subset of patients who present
with unresectable disease or those whose disease is resectable
but medically inoperable, deﬁnitive radiation is used instead
as the primary treatment. The surgical management of
endometrial cancer often involves simple hysterectomy and
BSO with or without lymph node staging. However, pelvicISRN Oncology 5
Table 3: Grade according stage in Mexican patients with endometrial carcinoma.
Stage (FIGO 1988) Grade 1
n = 165 (%)
Grade 2
n = 115 (%)
Grade 3
n = 130 (%)
Not speciﬁed
n = 2( % )
IA 40 (24.2) 3 (2.6) 3 (2.3) 0
IB 54 (32.7) 26 (22.6) 17 (13.1) 0
IC 26 (15.7) 16 (13.9) 37 (28.5) 1 (50)
IIA 19 (11.5) 17 (14.8) 17 (13.8) 1 (50)
IIB 8 (4.8) 20 (17.4) 13 (10) 0
IIIA 11 (6.7) 17 (14.8) 18 (13.8) 1 (50)
IIIB 1 (0.7) 0 0 0
IIIC 6 (3.7) 15 (13) 33 (2.4) 0
IVA 0 1 (0.9) 1 (0.7) 0
and para aortic lymph nodal sampling and dissection has
become a routine around the world, especially for patients
operated by gynecologic oncologists [13–15], although this
ultimate proceeding is controversial, two recent trials did not
show improvement in disease-free or overall survival after
lymphadenectomy in early-stage disease [16, 17]. Whether
the procedure is being performed by a gynecologist or
a gynecologic oncologist, the patient’s general condition,
the habitus of the patient, and several other factors aﬀect
the thoroughness of the lymphadenectomy. The minimum
number of lymph nodes that need to be retrieved for the
dissection to be representative has yet to be determined, and
theﬁnalevaluationofalymphadenectomyspecimenwillalso
depend on how meticulously the specimens are examined
by the pathologist. Also, pelvic lymph nodal involvement is
likely a marker for a biologically aggressive disease with a
propensity for distant failures; any pelvic radiation oﬀered in
that setting is aimed at essentially improving local-regional
control. However, the concern has been raised that omitting
lymphadenectomy in patients with grade 1 tumors may lead
to inappropriate postoperative treatment [18]. With regard
to the type of surgery in our study 120 patients were treated
with TAH-BSO, 20 patients with TAH-BSO-pelvic LND,
and271patientswithTAH-BSO-Pelvic/para-aorticLNDand
peritoneal washings and omentum biopsy.
Approximately 70–80% of patients with endometrial
cancer are diagnosed at stage I with a favorable prognosis
[17, 19, 20]. Because the concept of stage grouping is based
oncreatinggroupswithsimilarprognoses,itisnotsurprising
that the outcome gets less favorable with advancing stage.
Reported results of stage-based survival are remarkably
consistent, with stages I, II, III, and IV disease having 5-year
survival rates of 92%, 80%, 40%, and 5%, respectively [21].
In the present study, 221 (53.7%) of the patients had stage
I disease at the time of diagnosis, while 86 patients (20.9%)
had stage II, and 103 patients (24.9%) had stage III disease,
and 2 patients (0.5%) had stage IVA disease.
The low-risk group includes patients with stage IA G1,
G2 tumors. The risk of pelvic lymph nodal positivity [22]
is less than or equal to 3%, and the 5-year progression-free
survival rate in this group is on the order of 90% to 96%. It
is unlikely that postoperative pelvic external-beam radiation
would add anything to the ﬁnal outcome, and therefore
radiation is not routinely recommended to this group of
patients [23–26]. The role of intravaginal radiation in these
patients is also of questionable beneﬁt because of a very low
rate of vaginal recurrence with surgery alone. These patients
have the lowest risk of recurrence [27]. This was veriﬁed
by the ﬁndings of prospective studies conducted between
1977 and 1983 by the Gynecologic Oncology Group (GOG
33), which investigated the patterns of failure for early-stage
disease [22]. Of the women who had no myometrial invasion
with grade 1 or 2 histology, none experienced recurrence
[23]. In addition, a Cochrane review of the treatment for
stage I endometrial cancer found a statistically signiﬁcant
greater risk for death in patients who had EBRT versus no
treatment with low risk factors (i.e., disease conﬁned to
the endometrium, <50% myometrial invasion or grade 1/2)
[17]. These data were conﬁrmed again by meta-analysis of
seven randomized trials by Johnson and Cornes showing
that prophylactic EBRT could be harmful or ineﬀective in
improving survival in women with low- or intermediate-risk
cancer [19].
The intermediate-risk group has been deﬁned by the
GOG as those with pathologic stage IB to IIB (occult cervical
involvement). It is in this risk category in which most of
the controversy resides about the indication and type of
radiation needed. With regard to the indication of adju-
vant radiation in intermediate-risk patients, the controversy
relatestothelackofimprovementinoverallsurvivalwiththe
use of adjuvant radiation compared with surgery alone. The
two recently completed randomized trials demonstrating
lack of survival advantage leads to the conclusion that
adjuvant radiation is not needed. The policies for the use
of radiotherapy have changed compared with trials, where
EBRT + VBT were obligated for every patient operated with
endometrial carcinoma [13, 14]. With more common use
of lymphadenectomy during surgery, the value of adjuvant
pelvic RT given to lymph-node negative areas has become
questioned, and now patients from the intermediate risk
g r o u ps e e mt ob e n e ﬁ to n l yf r o ma d j u v a n tV B T[ 15, 16,
28]. The inclusion criteria for this group vary slightly from
trial to trial. These risk factors include, age, lymphovascular
space invasion, tumor size, cervical involvement, and deep6 ISRN Oncology
Table 4: Treatment characteristics of Mexican patients with endometrial carcinoma.
Characteristic Patients Percentage
Surgery
TAH-BSO 120 29.1
TAH-BSO-pelvic LND 20 4.9
TAH-BSO-Pelvic/para aortic LND and
omentum biopsy 271 65.8
Pelvic exenteration 1 .2
Lymph node dissection
Pelvic 296/412 71.8
Para aortic 273/412 66.3
Chemotherapy
Yes 59 14.3
No 353 85.7
Concurrent with RT 25/59 6.1
Sequential chemotherapy 31/59 7.5
Adjuvant without RT 3/59 .7
Chemotherapy agents used
Cisplatin/adriamicin 15 3.6
Cisplatin 2 .5
CisCA regimen 4 1.0
Carboplatin/adriamicin/ciclophosphamide 1 .2
PVC regimen 3 .7
Adriamicin 3 .7
Cisplatin/adriamicin/ciclophosphamide 1 .2
Ciclophosphamide/adriamicin 1 .2
Cisplatin/paclitaxel 2 .5
Carboplatin 22 5.3
Carboplatin/paclitaxel 4 1.0
Gemcitabine 1 .2
Hormone therapy
Yes 10 2.4
No 402 97.6
Radiotherapy
Yes 270 65.53
No 142 34.47
Pelvic EBRT 11/270 4.08
WART + pelvic RT + VBT 8/270 2.96
EBRT + VBT 241/270 89.26
VBT 7/270 2.59
Pelvic + retroperitoneum EBRT + VBT 3/270 1.11
Brachytherapy
Yes 255/412 61.89
No 157/412 38.11
High-dose rate 14/255 5.49
Low-dose rate 241/255 94.51
TAH-BSO: total abdominal hysterectomy, TAH-BSO-LND: total abdominal histerectomy and lymph node dissection, EBRT: external beam radiotherapy,
WART: whole abdominal radiotherapy, and VBT: vaginal vault brachytherapy.ISRN Oncology 7
Table 5: Multivariate analysis using cox regression model for
prognostic factors for overall survival in patients with endometrial
carcinoma.
Characteristic HR IC 95% P
Grade
11 . 0 0
2 3.40 1.62–7.09 0.0004
3 4.97 2.44–10.10
Serosal involvement
Yes 2.51 1.44–4.38 0.005
No 1.00
Adnexial involvement
Yes 2.31 1.25–4.30 0.005
No 1.00
Age (years)
<45 1.00
45–54 0.66 0.30–1.44
0.0003 55–64 0.97 0.50–1.89
65–74 1.33 0.63–2.82
>75 5.40 2.44–11.93
myometrial invasion. Despite multiple randomized studies,
this group is still the most controversial with regard to
adjuvant radiotherapy because it is not clear whether the
beneﬁt of treatment outweighs the risks. In a trial conducted
by Aalders et al., all patients received vaginal brachytherapy
and then were randomized to no further treatment or EBRT.
There was a signiﬁcant reduction in pelvic and vaginal
recurrences in patients who received EBRT although these
patients had more distant metastases. The 5-year overall
survival (OS) was not improved by EBRT, although a more
detailed analysis of the series concluded that patients with
higher risk factors such as poorly diﬀerentiated tumors
(grade 3), who have greater than 50% myometrial invasion
might beneﬁt from EBRT [29].
The Postoperative Radiation in Endometrial Cancer
(PORTEC 1) trial in which 714 patients with stage IB
G2,3 and IC G1,2 were randomized after TAH-BSO and
without lymph nodal sampling to observation (N = 360)
or pelvic radiation (N = 354) to a total dose of 46Gy
in 23 fractions. With a median followup of 52 months,
the 5-year locoregional control was 96% in the radiation
arm compared with 86% in the observation arm (P<
0.001). The corresponding 5-year survival rates were 81%
and 85%, respectively (P = 0.37) [16]. Recently a PORTEC
1 ﬁfteen year actualization conﬁrmed the highly signiﬁcant
improvement of local control obtained by EBRT but an
absenceofsurvivalbeneﬁt.Besides,atrendtodevelopsecond
primary cancers was found over 15 years in 19% of all
patients, 22% versus 16% for EBRT versus no additional
treatment (P = 0.10), with observed versus expected ratios
of 1.6 (EBRT) and 1.2 (no additional treatment) compared
withamatchedpopulation(P =NS)[30].Oftherandomized
studies, the GOG 99 study was the only study that required
FIGO surgical staging. three hundred ninety-two patients
with stage IB to IIB endometrial cancer who underwent
TAH-BSO and pelvic and para aortic lymph nodal sampling
were randomized to observation (N = 202) or postoperative
pelvic radiation (N = 190) to a total dose of 50.4Gy in 28
fractions. The study was designed to have an 80% chance of
detecting a 58% decrease in the recurrence hazard rate and
a 56% decrease in death hazard rate. The primary outcome
was recurrence-free interval and is deﬁned as the time from
study entry to clinical, histologic, or radiographic evidence
of disease recurrence. With a median followup of 69 months,
the 2-year cumulative incidence of recurrence was 12% in
the observation group and 3% in the adjuvant radiotherapy
group. This was statistically signiﬁcant (P = 0.007). The
estimated 4-year survival rate was 86% in the observation
group, compared with 92% in the irradiated group. This
was not a statistically signiﬁcant diﬀerence (P = 0.557)
[31] .Ar e c u r r e n c er a t eo f1 2 – 1 4 %w a sr e p o r t e di np a t i e n t s
treated with surgery alone in PORTEC and GOG-99 trials,
with isolated vaginal recurrence as the most common form
of recurrent disease [16, 31]. With regard to side eﬀects,
a complication rate of 25% and 15%, respectively, was
reported for patients receiving pelvic RT in these two trials.
The complication rate associated with the pelvic irradiation
in the GOG-99 study was much higher than that in the
PORTEC study, probably because of the extent of surgical
staging. The rate of severe (grade 3 or 4) gastrointestinal
toxicity with radiation were 8% in the GOG study but only
3% in the PORTEC trial. In our study, 17% of the patients
h a dR T O Gg r a d e1 - 2l a t es i d ee ﬀects mainly gastrointestinal
eﬀects, with 3 patients having grade 3-4 side eﬀects.
The ASTEC-EN5 trial, which is a pooled meta-analysis
of two randomized trials (ASTEC and EN.5), was designed
to evaluate the beneﬁt of postoperative adjuvant EBRT
in women with intermediate- and high-risk early-stage
endometrial cancer. Between 1996 and 2005, 905 patients
with intermediate-risk or high-risk endometrial cancer were
randomly assigned to observation or external-beam radio-
therapy. Vaginal brachytherapy was allowed based on each
center’s policy. As a result, 51% of the observation group
received vaginal brachytherapy. Not surprisingly, the analysis
did not ﬁnd any evidence of overall survival beneﬁt with
external-beam radiotherapy [32].
The only trial comparing VBT versus RT is the second
study in the PORTEC series. This noninferiority multicenter
trial randomized patients with a high intermediate risk of
recurrence deﬁned as age 60 years and above and stage IC
grades 1 or 2 or stage IB grade 3, and any age with stage
IIA grades 1, 2 or grade 3 with less than 50% invasion.
A total of 427 patients were recruited to this trial between
2002 and 2006, with a median follow-up time of 45 months.
There was no signiﬁcant diﬀerence in OS and the 5-year
locoregional recurrence rate between treatment modalities.
The lack of diﬀerence in survival in PORTEC-2 raises the
question of whether adjuvant therapy is needed at all for
patients with intermediate-risk disease. The estimated 5-year
vaginal recurrence rates were 1.8% (95% CI) after VBT and
1.6% (95% CI) after EBRT [33]. Regarding the quality of life8 ISRN Oncology
for patients enrolled in this study, the EBRT group reported
signiﬁcant and clinically relevant higher levels of diarrhea
and fecal leakage, which limited social and daily activities for
the EBRT group (P<0.001) [34].
It is well known that pelvic RT helps to reduce locore-
gional recurrences and mortality in patients with multiple
high risk factors (myometrial invasion greater than 50%,
grade 3, gross involvement of the cervix or advanced-stage
disease, lymphovascular space involvement, and aggressive
histologic types) but with no beneﬁt for the risk of distant
metastases. In 2004, Creutzberg and colleagues [35]r e p o rt e d
their ﬁndings for 104 patients with stage IC, grade 3 tumors
who had registered but were not included in the ﬁrst
PORTEC trial, comparing their survival with that of the pa-
tients included in that trial. Grade 3 tumors were found to
haveamuchhighermetastasisratethangrades1or2tumors;
multivariate analysis showed that histologic grade 3 was the
most important adverse prognostic factor for relapse and
death from endometrial cancer. These ﬁndings raise the
question of whether radiation alone is enough for grade 3
tumors or whether the better, strategy may be a combination
of radiation and chemotherapy. For such patients, chem-
otherapy (CT) has been proposed as a potentially beneﬁ-
cial therapeutic approach with randomized controlled trials
speciﬁc to this exact subset of patients. Multiple studies have
addressed which treatment might be better should they be
combined, and if combined, what chemotherapy should be
used. Still, the search for eﬀective cytotoxic agents for the
treatment of endometrial carcinoma continues. To date only
three drugs with deﬁnite activity have been identiﬁed:
doxorubicin, cisplatin, and paclitaxel [36].
Early results of a study done by the Nordic Society of
Gynecologic Oncology and the European Organization for
Research and Treatment of Cancer were presented at the
American Society of Clinical Oncology meeting in May 2007
[37]. The NSGO-EC-9501/EORTC-55991 trial randomly
assigned 382 patients between 1996 and 2007 to receive adju-
vant radiation therapy (n = 196) or radiation therapy plus
chemotherapy (n = 186). Patients with surgical stages I,
II, IIIA (positive peritoneal ﬂuid cytology only), or IIIC
(positive pelvic lymph nodes only) disease were eligible if
they were considered to be at suﬃciently high risk for
micrometastatic disease to qualify for adjuvant therapy.
Patients with serous, clear cell, or anaplastic carcinomas
were eligible regardless of risk factors. Patients with para
aortic metastases were not eligible. Lymph node exploration
at surgical staging was optional. All patients underwent at
least a total abdominal hysterectomy with bilateral salpingo-
oophorectomy. Pelvic radiation therapy, with or without
vaginal brachytherapy, was given to a dose of 44Gy. Chem-
otherapy was given before or after the radiation. Before
August 2004, the chemotherapy regimen consisted of four
courses of cisplatin and doxorubicin or epirubicin; after
that time, several chemotherapy regimens were allowed.
The median follow-up time was 4.3 years. The hazard
ratio for progression-free survival in the study was 0.62
(95% CI, 0.40 to 0.97; P = 0.03), which translated to an
estimated difference in 5-year progression-free survival rate
of 7% (from 72% for those given radiation to 79% for those
given chemoradiation therapy) [37]. The corresponding
ﬁndings for overall survival were similar; the hazard ratio
w a s0 . 6 5( 9 5 %C I ,0 . 4 0t o1 . 0 6 ;P = .08), for an estimated
diﬀerence in 5-year overall survival rate of 8% (74% for
radiation versus 82% for chemoradiation therapy). The
investigators concluded thateventhough27% ofthe patients
assigned to the chemoradiation therapy group received little
or none of the prescribed chemotherapy, chemoradiation
therapy was still better than radiation alone for patients with
early endometrial cancer at high risk for micrometastasis
[37]. The Japanese GOG was a randomized study that
enrolled 475 patients with stages IC–IIIC endometrial car-
cinoma with deeper than 50% myometrial invasion (FIGO
1988 criteria). They were randomized to receive adjuvant
EBRT or cyclophosphamide, doxorubicin, and cisplatin. A
pelvic lymphadenectomy was performed in 96.1% of the
patients and a para aortic lymphadenectomy was performed
in 28.6%. The OS and PFS were not statistically diﬀerent
between the two arms. In their subgroup analysis of HIR
patients, they found a signiﬁcant beneﬁt in PFS rate (P =
0.24) and OS rate (P = 0.006) for the chemotherapy group
[38]. In the present study, 3 patients received CT alone, 25
concurrently with RT and 31 in sequential mode (CT ﬁrst).
For many years, adjuvant wide-ﬁeld RT+CT has been
used for advanced stage patients [39, 40]. However, GOG-
122 study recruiting stages III-IV patients showed a survival
advantage for CT alone compared to whole-abdominal RT
[39]. Eight patients in our study received whole abdominal
RT and during the postoperative period, among stage III pa-
tients, three received para aortic RT+BRT, and 241 received
pelvic RT+BRT.
The following risk factors were identiﬁed in studies eval-
uatingtheprognosisinendometrialcancer:ageatthetimeof
diagnosis, menopausal status, stage, tumor size, histological
type, grade, depth of the myometrial invasion, cervical,
stromal and lymphovascular invasion, adnexial involvement,
intraperitoneal involvement, positive peritoneal cytology,
and pelvic and para aortic lymph node involvement [25,
34, 41]. In our study, the signiﬁcance of these factors was
examinedwithunivariateandmultivariateanalyses,showing
statistical signiﬁcance for overall survival for age, grade, and
serosal and adnexial involvement (P = 0.05).
The overall survival at 2, 5, and 10 years was 95%, 84%,
and 79.4%, respectively, these results are consistent with oth-
ers reported in the literature [28]. After a mean followup of
49 months, 338 patients (82%) were still alive without dis-
ease,13(3%)werealivewithdisease,and85(21%)weredead
by the time this analysis was done. Recurrences presented in
the ﬁrst two years after treatment in 18% of patients being
vaginal and locoregional (pelvic) the most common.
6. Conclusion
This retrospective analysis of 412 women with endometrial
cancer reveals statistically signiﬁcant diﬀerences in patho-
logic disease characteristics among those with adenocar-
cinoma of the endometrium receiving surgery alone or
surgery followed by adjuvant RT at our institution. DespiteISRN Oncology 9
endometrial carcinoma being one of the most common
gynecologic malignancies in female tract, controversy exists
regarding the role of adjuvant radiotherapy. Despite the
statisticallysigniﬁcantbeneﬁtofadjuvantRTonlocalcontrol
observed in the adjusted analysis, we recognize that this
is a retrospective study that is prone to inherent bias.
Important pathologic and clinical factors, including tumor
diameter, lymphovascular space invasion, adequate lymph
node evaluation, and positive peritoneal washings, were
not suﬃciently represented to allow for evaluation and
adjustment in this series’ analysis. We recognize the potential
biases that these and other factors can introduce into an
analysis of this kind and do not espouse these data as
deﬁnitive proof of the beneﬁt of RT in the adjuvant setting.
To our knowledge, this is the largest series exploring the
characteristics of Mexican patients treated for endometrial
carcinoma in the literature. We conclude that adjuvant
radiotherapy should be considered an integral component
of deﬁnitive treatment for women with unfavorable disease
as a mean to decrease mortality and improve patient
outcome. Future work is needed to delineate clinical and
biologic factors that can guide treatment and account for
disparities in outcomes between subsets of women with
endometrial carcinoma, including patterns of care analyses
and prospective studies of adjuvant radiotherapy modalities
and tumor-speciﬁc treatment strategies.
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